I forgot to mention that CF33 can be loaded with a wide variety of payloads.
Importantly this includes drugs from other companies, already approved drugs.
So the licensing opportunities are substantial, that’s why I doubt the company will be bought out. There is so many opportunities to do great licensing deals.
But if the BOD did accept a buyout the number will be jaw dropping stuff.
As has been previously posted there are at least 60 different cancers that can be targeted by CF33. So it could be Cancer-CF33-Drug. That’s a lot of opportunities.
We will know in less than 12 months maybe as soon as 6 months if I’m hearing LC’s latest video correctly.
Ann: Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA, page-73
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |